iQure Signs Supply Agreement for 'Donepezil Patch' with Celltrion
iCure announced on the 22nd that it has signed a license and product supply agreement with Celltrion for the sale of donepezil patches in 17 Latin American countries.
The supplied products are two types of donepezil patches, 87.5mg and 175mg, and the sales regions include 17 Latin American countries such as Brazil, Mexico, Chile, and Colombia.
Through this contract, iCure is expected to receive a contract fee of 300 million KRW, development milestones up to 2.9 billion KRW, and sales milestones up to 4.6 billion KRW. However, the contract fee may be refunded depending on the results of the due diligence of the approval documents. Milestones can be received when approval, launch, and sales conditions are met within the respective regions.
Hot Picks Today
"Wow, Have Middle-Aged Men Had This All to Themselves?"... Women in Their 20s and 30s Find Comfort in a Standing Drink
- "Koreans Spend 1 Million Won Each and Come Back"... 'They Said They Were Going for Value for Money,' but Open Their Wallets Wide in Japan
- U.S. Treasury Yields Are Falling... Why Is the KOSPI Still Reeling?
- "Naked Again?" Controversial Actress Crosses a Line... Slammed for Sexualizing 'Child Characters'
- "A Cream Costing 15,000 Won to Make Sells for 350,000 Won"... The 'Break-Even Point' That Fits Strangely Well
The contract termination date is 10 years from the start of sales.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
